Increased expression of HDAC1, HDAC2, HDAC3 and HDAC6 are reported in several cancers including colon, prostate and breast cancer and inhibition of HDACs potentially could target proliferation, differentiation, angiogenesis, and migration [206]. Here, HDAC3 is linked to breast carcinoma.